参考文献/References:
[1]Ralapanawa U,Sivakanesan R. Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome:a narrative review[J]. J Epidemiol Glob Health,2021,11(2):169-177.
[2]Li J,Li X,Ross JS,et al. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011:China PEACE-retrospective AMI study [J]. Eur Heart J Acute Cardiovasc Care,2017,6(3):232-243.
[3] 卫靖靖,朱明军,王永霞,等. 心肌梗死中医健康监测的临床研究述评[J]. 中国中医基础医学杂志,2023,29(5):861-864.
[4] 复杂冠心病血运重建心脏团队决策研究协作组. 复杂冠心病血运重建策略内外科专家共识[J]. 中国循环杂志,2022,37(11):1073-1085.
[5] 北京护理学会心血管专业委员会. 冠心病患者心脏康复健康教育处方护理专家共识[J]. 中华现代护理杂志,2022,28(9):1121-1127.
[6]Bae JW,Woo SI,Lee J,et al. mHealth interventions for lifestyle and risk factor modification in coronary heart disease:randomized controlled trial[J]. JMIR Mhealth Uhealth,2021,9(9):e29928.
[7]Javdan B,Lopez JG,Chankhamjon P,et al. Personalized mapping of drug metabolism by the human gut microbiome[J]. Cell,2020,181(7):1661-1679.e22.
[8]Krautkramer KA,Fan J,B?ckhed F. Gut microbial metabolites as multi-kingdom intermediates[J]. Nat Rev Microbiol,2021,19(2):77-94.
[9]Nakajima A,Mitomo S,Yuki H,et al. Gut microbiota and coronary plaque characteristics[J]. J Am Heart Assoc,2022,11(17):e026036.
[10]Liu H,Chen X,Hu X,et al. Alterations in the gut microbiome and metabolism with coronary artery disease severity[J]. Microbiome,2019,7(1):68.
[11]Zheng X,Li J,Gou Y,et al. Changes in intestinal flora from chronic renal failure complicated with coronary heart disease and its correlation with arterial stiffness index[J]. Altern Ther Health Med,2023,29(1):252-257.
[12]Jia J,Dou P,Gao M,et al. Assessment of causal direction between gut microbiota-dependent metabolites and cardiometabolic health:a bidirectional Mendelian randomization analysis[J]. Diabetes,2019,68(9):1747-1755.
[13]Kim M,Huda MN,Bennett BJ. Sequence meets function-microbiota and cardiovascular disease[J]. Cardiovasc Res,2022,118(2):399-412.
[14]邢团结,娄焕堃,李鹏,等. 血清氧化三甲胺水平与冠心病及冠状动脉狭窄程度的相关性分析[J]. 蚌埠医学院学报,2023,48(4):466-469,473.
[15]Amrein M,Li XS,Walter J,et al. Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)[J]. Clin Res Cardiol,2022,111(6):692-704.
[16]Sardu C,Consiglia Trotta M,Santella B,et al. Microbiota thrombus colonization may influence athero-thrombosis in hyperglycemic patients with ST segment elevation myocardialinfarction(STEMI). Marianella study[J]. Diabetes Res Clin Pract,2021,173:108670.
[17]Chen W,Zhang S,Wu J,et al. Butyrate-producing bacteria and the gut-heart axis in atherosclerosis[J]. Clin Chim Acta,2020,507:236-241.
[18]Anto L,Blesso CN. Interplay between diet,the gut microbiome,and atherosclerosis:role of dysbiosis and microbial metabolites on inflammation and disordered lipid metabolism[J]. J Nutr Biochem,2022,105:108991.
[19]Luo T,Guo Z,Liu D,et al. Deficiency of PSRC1 accelerates atherosclerosis by increasing TMAO production via manipulating gut microbiota and flavin monooxygenase 3[J]. Gut Microbes,2022,14(1):2077602.
[20]陈嫚,刘洪涛,林相豪,等. 基于肠道菌群及胆汁酸代谢探讨动脉粥样硬化的发病机制[J]. 现代中西医结合杂志,2022,31(5):709-713.
[21]Sieckmann T,Kirschner KM. Polyamines,metabolites and metabolomics[J]. Acta Physiol (Oxf),2020,229(3):e13480.
[22]Lin Y,Wu SH,Wang XH,et al. Associations of imbalance of intestinal flora with severity of disease,inflammatory factors,adiponectin,and vascular endothelial function of hypertension patients[J]. Kaohsiung J Med Sci,2022,38(2):165-173.
[23]Tsutsumi R,Yamasaki Y,Takeo J,et al. Long-chain monounsaturated fatty acids improve endothelial function with altering microbial flora[J]. Transl Res,2021,237:16-30.
[24]Wang Z,Hazen J,Jia X,et al. The nutritional supplementL-alpha glycerylphosphorylcholine promotes atherosclerosis[J]. Int J Mol Sci,2021,22(24):13477.
[25]Bartolomaeus H,Balogh A,Yakoub M,et al. Short-chain fatty acid propionate protects from hypertensive cardiovascular damage[J]. Circulation,2019,139(11):1407-1421.
[26]Zhang XN,Yu ZL,Chen JY,et al. The crosstalk between NLRP3 inflammasome and gut microbiome in atherosclerosis[J]. Pharmacol Res,2022,181:106289.
[27]陈雯雯,拜年,管娜,等. 基于网络药理学和分子对接探讨黄连治疗高脂血症的作用机制[J].新疆医科大学学报,2022,45(9):1020-1028.
[28]徐卓,项想,尚尔鑫,等. 丹参茎叶总酚酸对2型糖尿病肾病小鼠肠道菌群和短链脂肪酸的调节作用[J]. 药学学报,2021,56(4):1035-1048.
[29]黄敏,杨燕.丹参酮ⅡA联合CASC2对甲状腺癌细胞增殖、凋亡、迁移、侵袭的影响[J].中国细胞生物学学报,2021,43(5):947-955.
[30]吴睿婷,付王威,万敏,等. 黑灵芝多糖对糖尿病大鼠血糖血脂调节及肠道菌群的影响[J]. 食品科学,2022,43(5):91-102.
[31]Zhang Y,Gu Y,Chen Y,et al. Dingxin Recipe IV attenuates atherosclerosis by regulating lipid metabolism through LXR-α/SREBP1 pathway and modulating the gut microbiota in ApoE-/-?mice fed with HFD[J]. J Ethnopharmacol,2021,266:113436.
[32]Li X,Liu Y,Guo X,et al. Effect of Lactobacillus casei on lipid metabolism and intestinal microflora in patients with alcoholic liver injury[J]. Eur J Clin Nutr,2021,75(8):1227-1236.
[33]Yadav R,Khan SH,Mada SB,et al. Consumption of probiotic Lactobacillus fermentum MTCC:5898-fermented milk attenuates dyslipidemia,oxidative stress,and inflammation in male rats fed on cholesterol-enriched diet[J]. Probiotics Antimicrob Proteins,2019,11(2):509-518.
[34]Xu D,Feng M,Chu Y,et al. The prebiotic effects of oats on blood lipids ,gut microbiota,and short-chain fatty acids in mildly hypercholesterolemic subjects compared with rice:a randomized,controlled trial[J]. Front Immunol,2021,12:787797.
[35]Pathak P,Helsley RN,Brown AL,et al. Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism[J]. Am J Physiol Heart Circ Physiol,2020,318(6):H1474-H1486.
[36]Lei L,Zhao N,Zhang L,et al. Gut microbiota is a potential goalkeeper of dyslipidemia[J]. Front Endocrinol (Lausanne),2022,13:950826.
[37]Huang WC,Tung CL,Yang YSH,et al. Endurance exercise ameliorates Western diet-induced atherosclerosis through modulation of microbiota and its metabolites[J]. Sci Rep,2022,12(1):3612.
[38]Luissint AC,Williams HC,Kim W,et al. Macrophage-dependent neutrophil recruitment is impaired under conditions of increased intestinal permeability in JAM-A-deficient mice[J]. Mucosal Immunol,2019,12(3):668-678.
[39]Terzo S,Mulè F,Caldara GF,et al. Pistachio consumption alleviates inflammation and improves gut microbiota composition in mice fed a high-fat diet[J]. Int J Mol Sci,2020,21(1):365.
[40]Zeng S,Yi R,Tan F,Sun P,et al. Lactobacillus plantarum?HFY05 attenuates carrageenan-induced thrombosis in mice by regulating NF-κB pathway-associated inflammatory responses[J]. Front Nutr,2022,9:813899.
[41]雍晨,黄国顺,葛宏伟,等. 中医药调节肠道菌群代谢产物氧化三甲胺干预慢性肾脏病及其并发症的研究进展[J]. 中国中药杂志,2023,48(2):321-328.
[42]Reiner MF,Müller D,Gobbato S,et al. Gut microbiota-dependent trimethylamine-N-oxide(TMAO) shows a U-shaped association with mortality but not with recurrent venous thromboembolism[J]. Thromb Res,2019,174:40-47.
[43]Vadaq N,Schirmer M,Tunjungputri RN,et al. Untargeted plasma metabolomics and gut microbiome profiling provide novel insights into the regulation of platelet reactivity in healthy individuals[J]. Thromb Haemost,2022,122(4):529-539.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(2):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(2):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(2):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(2):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(2):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(2):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(2):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(2):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]